Genentech Inc.’s multiple sclerosis therapy Ocrevus (ocrelizumab) will reach the US market in the next few weeks now that the Roche unit has overcome a regulatory hurdle that extended FDA’s review process.
On March 28, FDA approved ocrelizumab, a CD20-directed cytolytic antibody, for the treatment of patients with relapsing or